hit counter
Altimmune, Inc. (ALT) Stock News Sentiment & Price - Sentifly
ALT - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Altimmune, Inc. (ALT)

USA
Biotechnology
NASDAQ
ALT Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ALT Latest news
GlobeNewsWire
Neutral
Altimmune to Present at Upcoming Investor Conferences
2021-11-10 16:01

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be presenting virtually at the following investor conferences in November 2021:

Seeking Alpha
Neutral
Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2021 Results - Earnings Call Transcript
2021-11-10 12:32

Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Altimmune, Inc. (ALT) Reports Q3 Loss, Tops Revenue Estimates
2021-11-09 19:49

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of -125.00% and 49.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
2021-11-09 16:01

Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment

GlobeNewsWire
Neutral
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
2021-11-03 16:01

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.

Zacks Investment Research
Negative
Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2021-11-01 16:06

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha
Neutral
Altimmune: Changing The Thesis
2021-10-16 04:05

Altimmune has been one of the top-performing stocks in our speculative portfolio. The company recently reported encouraging results from their NASH candidate, ALT-801. The market has been bullish on ALT since they announced their COVID-19 programs, but now it is time to turn our attention to ALT-801. I believe ALT-801 is their flagship.

PRNewsWire
Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
2021-10-15 21:35

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S.

GlobeNewsWire
Neutral
Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
2021-10-06 16:01

GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences:

Newsfile Corp
Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
2021-10-01 17:15

New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

Loading more news...